Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUNE-LUNG
2020-005562-34Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, nivolumab and atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut Bergonié. Primary endpoint: 12-month progression-free rate. Started Feb 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005562-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005562-34.